Hypothesis

Female mammals exhibit a consistent lifespan advantage that correlates with XX chromosome dosage, yet the immunological mediators of this benefit remain undefined. We propose that escape from X‑chromosome inactivation (XCI) of the histone demethylase KDM6A (UTX) yields higher KDM6A expression in XX eosinophils, reprogramming their epigenome to favor a tissue‑repair (M2‑like) phenotype. This eosinophil‑driven repair enhances muscle homeostasis and resilience to age‑related damage, contributing directly to the observed longevity gap.

Rationale

• XCI escape and dosage – Approximately 25 % of X‑linked genes escape inactivation, creating a bimodal expression landscape that can boost protein dosage in females 1. KDM6A is a well‑documented escapee, showing ~1.5‑fold higher transcript levels in female immune cells 2.
• KDM6A function in immunity – KDM6A demethylates H3K27me3, promoting transcription of genes involved in alternative macrophage activation and IL‑4/IL‑13 signaling 3. In eosinophils, IL‑4/IL‑13 signaling drives a pro‑repair phenotype characterized by elevated ARG1, CHI3L1, and VEGF‑A production.
• Eosinophils in tissue repair – Beyond their classic role in helminth immunity, eosinophils are indispensable for muscle regeneration, fibro‑adipogenic progenitor (FAP) modulation, and attenuation of fibrosis after injury 4. Sex‑biased differences in eosinophil‑mediated repair have been noted but never mechanistically linked to X‑chromosome dosage.

Mechanistic Model

1. Higher KDM6A dosage in XX eosinophils reduces H3K27me3 at promoters of Arg1, Chi3l1, and Vegfa, increasing their transcription.
2. This epigenetic shift biases eosinophils toward an IL‑4/IL‑13‑responsive, pro‑repair state that secretes anti‑inflammatory and angiogenic factors.
3. In skeletal muscle, these eosinophils enhance satellite cell activation and limit fibro‑fatty infiltration, preserving contractile tissue with age.
4. The cumulative effect is improved tissue resilience and delayed onset of sarcopenia, a major contributor to mortality disparity between sexes.

Testable Predictions

• Prediction 1: XX mice will show ~1.5‑fold higher Kdm6a mRNA and protein in bone‑marrow‑derived eosinophils compared with XY counterparts.
• Prediction 2: Conditional knockout of Kdm6a specifically in eosinophils (using Epx‑Cre; Kdm6a^fl/fl) will abolish the sex difference in eosinophil ARG1 and CHI3L1 expression after muscle injury.
• Prediction 3: Epx‑Cre; Kdm6a^fl/fl XX mice will exhibit reduced muscle regenerative capacity (lower centrally nucleated fibers, increased fibrosis) and shortened lifespan relative to control XX mice, bringing their survival curves closer to those of XY mice.
• Prediction 4: Adoptive transfer of wild‑type XX eosinophils into Kdm6a‑deficient XX recipients will rescue the repair phenotype and extend lifespan, whereas XY eosinophils will have a weaker effect.

Experimental Approach

1. Cellular assays – Isolate eosinophils from bone marrow of XX and XY mice (Four Core Genotypes to separate chromosomal vs hormonal effects). Quantify Kdm6a, H3K27me3 at target loci (ChIP‑qPCR), and repair‑gene expression (RT‑PCR, flow cytometry for intracellular ARG1).
2. In vivo injury model – Induce cardiotoxin‑mediated tibialis anterior injury. Track eosinophil influx (flow cytometry), muscle histology (H&E, Masson’s trichrome), and functional recovery (grip strength, treadmill endurance).
3. Longevity study – Monitor survival cohorts of control, eosinophil‑specific Kdm6a KO, and rescue groups (n ≥ 150 per sex) under standard housing; perform Kaplan‑Meier analysis with log‑rank test.
4. Human validation – Analyze publicly available single‑cell RNA‑seq datasets of human blood eosinophils from GTEx and Tabula Sapiens for KDM6A expression bias between sexes; correlate with eosinophil signatures of tissue repair (ARG1, CCL24).

Potential Impact

Confirming that an X‑linked epigenetic regulator shapes eosinophil function would re‑frame the X chromosome as a dynamic modulator of immune‑mediated tissue maintenance, not merely a passive carrier of sex‑determining genes. It would also suggest therapeutic avenues—such as boosting KDM6A activity or eosinophil‑derived repair factors—to mitigate age‑related decline in both sexes, thereby addressing a fundamental mechanism behind the longevity gap.